Long Waits at Athens EOPYY Pharmacies Expose Healthcare System Strain
Long queues at Athens' EOPYY pharmacies cause significant delays for patients needing high-cost medications, highlighting understaffing and insufficient geographical distribution of these facilities, impacting patients' health and well-being.
Long Waits at Athens EOPYY Pharmacies Expose Healthcare System Strain
Long queues at Athens' EOPYY pharmacies cause significant delays for patients needing high-cost medications, highlighting understaffing and insufficient geographical distribution of these facilities, impacting patients' health and well-being.
Progress
56% Bias Score
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Medicare Selects 15 More Drugs for Price Negotiation
Medicare selected 15 more top-selling prescription drugs for price negotiations under the Inflation Reduction Act, impacting 5.3 million beneficiaries and $41 billion in spending, with expected savings of $1.5 billion in 2027, but the incoming Trump administration may alter the program.
Progress
48% Bias Score
575 Brand-Name Drug Prices Increase in Early 2025
On January 1st and 2nd, 2025, 575 brand-name drugs increased in price, including Ozempic and Paxlovid; the median increase was 4%, exceeding inflation and potentially impacting consumer costs depending on insurance coverage and formulary placement.
575 Brand-Name Drug Prices Increase in Early 2025
On January 1st and 2nd, 2025, 575 brand-name drugs increased in price, including Ozempic and Paxlovid; the median increase was 4%, exceeding inflation and potentially impacting consumer costs depending on insurance coverage and formulary placement.
Progress
36% Bias Score
China's Plan to Become a Pharmaceutical Powerhouse by 2035
China's State Council issued a guideline to transform its pharmaceutical industry into a global powerhouse by 2035, outlining 24 reform measures to enhance innovation, improve regulatory efficiency, and strengthen safety and quality controls, with 2024 showing 48 innovative drugs and 65 medical devi...
China's Plan to Become a Pharmaceutical Powerhouse by 2035
China's State Council issued a guideline to transform its pharmaceutical industry into a global powerhouse by 2035, outlining 24 reform measures to enhance innovation, improve regulatory efficiency, and strengthen safety and quality controls, with 2024 showing 48 innovative drugs and 65 medical devi...
Progress
44% Bias Score
Medical Breakthroughs Offer Hope for AIDS, Schizophrenia, and Alzheimer's
New semi-annual HIV treatment lenacapavir, novel schizophrenia drug 'Copenfi', and Alzheimer's drug Lecanemab offer hope but face cost and accessibility challenges.
Medical Breakthroughs Offer Hope for AIDS, Schizophrenia, and Alzheimer's
New semi-annual HIV treatment lenacapavir, novel schizophrenia drug 'Copenfi', and Alzheimer's drug Lecanemab offer hope but face cost and accessibility challenges.
Progress
40% Bias Score
Pharmaceutical Industry Faces 2025 Inflection Point Amidst Global Cost Pressures
Global pharmaceutical manufacturers face increasing pressure to lower drug prices in 2025 due to government regulations (e.g., the Inflation Reduction Act), payer consolidation, and consumer cost concerns; requiring manufacturers to prioritize long-term value, evidence-based decision-making, and str...
Pharmaceutical Industry Faces 2025 Inflection Point Amidst Global Cost Pressures
Global pharmaceutical manufacturers face increasing pressure to lower drug prices in 2025 due to government regulations (e.g., the Inflation Reduction Act), payer consolidation, and consumer cost concerns; requiring manufacturers to prioritize long-term value, evidence-based decision-making, and str...
Progress
44% Bias Score
LVMH Overtakes Novo Nordisk as Europe's Most Valuable Company
LVMH has overtaken Novo Nordisk as Europe's most valuable company, with a market cap of €341 billion versus Novo Nordisk's €261 billion, due to strong performance in the luxury sector and concerns about Novo Nordisk's pricing in the US.
LVMH Overtakes Novo Nordisk as Europe's Most Valuable Company
LVMH has overtaken Novo Nordisk as Europe's most valuable company, with a market cap of €341 billion versus Novo Nordisk's €261 billion, due to strong performance in the luxury sector and concerns about Novo Nordisk's pricing in the US.
Progress
36% Bias Score
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Medicare Price Negotiations Expand to 15 Drugs, Including Ozempic and Wegovy
The Biden administration announced 15 drugs, including Ozempic and Wegovy, for Medicare price negotiations under the Inflation Reduction Act, aiming to lower drug costs for 50 million beneficiaries; the new prices are expected to take effect in January 2027, although the incoming Trump administratio...
Progress
36% Bias Score
J&J's Lung Cancer Drug Extends Life by at Least a Year
Johnson & Johnson announced Tuesday that its two-drug lung cancer regimen, Rybrevant and Lazcluze, extends life expectancy by at least a year compared to AstraZeneca's Tagrisso, based on a pivotal trial, though the regimen has more side effects.
J&J's Lung Cancer Drug Extends Life by at Least a Year
Johnson & Johnson announced Tuesday that its two-drug lung cancer regimen, Rybrevant and Lazcluze, extends life expectancy by at least a year compared to AstraZeneca's Tagrisso, based on a pivotal trial, though the regimen has more side effects.
Progress
60% Bias Score
Biotech Stocks Poised for 2025 Rebound
Biotech stocks are poised for a rebound in 2025, driven by increased merger and acquisition activity, new drug approvals, and a looming patent cliff forcing large pharmaceutical companies to seek innovative biotech partners; however, investors should focus on specific companies rather than broad ind...
Biotech Stocks Poised for 2025 Rebound
Biotech stocks are poised for a rebound in 2025, driven by increased merger and acquisition activity, new drug approvals, and a looming patent cliff forcing large pharmaceutical companies to seek innovative biotech partners; however, investors should focus on specific companies rather than broad ind...
Progress
48% Bias Score
Quiet Christmas Eve Trading: Yields Rise, FDA Ends Zepbound Shortage
On December 24th, U.S. stock futures were mostly unchanged, while the 10-year and 30-year Treasury yields hit their highest points since May 30th and April 26th, respectively; all U.S. markets closed at 1 p.m. ET, and low trading volume is expected.
Quiet Christmas Eve Trading: Yields Rise, FDA Ends Zepbound Shortage
On December 24th, U.S. stock futures were mostly unchanged, while the 10-year and 30-year Treasury yields hit their highest points since May 30th and April 26th, respectively; all U.S. markets closed at 1 p.m. ET, and low trading volume is expected.
Progress
36% Bias Score
Market Shows Mixed Reaction to Positive and Negative News
Mixed market reactions to recent news include slightly higher stock prices, a strengthening dollar, and decreasing oil and gold prices; Apple explores home security devices, potentially leading to record iPhone sales; labor disputes affect Amazon and Starbucks; Honda and Nissan explore a potential m...
Market Shows Mixed Reaction to Positive and Negative News
Mixed market reactions to recent news include slightly higher stock prices, a strengthening dollar, and decreasing oil and gold prices; Apple explores home security devices, potentially leading to record iPhone sales; labor disputes affect Amazon and Starbucks; Honda and Nissan explore a potential m...
Progress
44% Bias Score